Actelion plans to tell investors today that it stopped the phase III clinical trial of Veletri, a proposed treatment for acute heart failure, because the study failed to show effectiveness. The study's steering committee recommended stopping the trial because 1,300 patients showed no statistically significant results. No safety issues surfaced in the trial, the firm said.

Full Story:

Related Summaries